VanEck Pharmaceutical ETF (NASDAQ:PPH) Hits New 12-Month High – Should You Buy?

Shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Get Free Report) reached a new 52-week high during trading on Monday. The company traded as high as $124.17 and last traded at $123.36, with a volume of 24,157 shares traded. The stock had previously closed at $122.65.

VanEck Pharmaceutical ETF Stock Up 0.4%

The business has a 50-day simple moving average of $113.65 and a two-hundred day simple moving average of $108.68. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of 29.81 and a beta of 0.43.

VanEck Pharmaceutical ETF Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, October 6th. Stockholders of record on Thursday, October 1st were paid a $0.36 dividend. The ex-dividend date of this dividend was Thursday, October 1st. This represents a $1.44 dividend on an annualized basis and a dividend yield of 1.2%. This is a drop from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.6248.

Institutional Investors Weigh In On VanEck Pharmaceutical ETF

Institutional investors and hedge funds have recently bought and sold shares of the business. TD Waterhouse Canada Inc. grew its holdings in shares of VanEck Pharmaceutical ETF by 130.0% during the second quarter. TD Waterhouse Canada Inc. now owns 230 shares of the company’s stock valued at $25,000 after buying an additional 130 shares in the last quarter. Arkadios Wealth Advisors raised its position in VanEck Pharmaceutical ETF by 1.8% during the first quarter. Arkadios Wealth Advisors now owns 8,447 shares of the company’s stock valued at $877,000 after acquiring an additional 150 shares in the last quarter. Axxcess Wealth Management LLC raised its holdings in shares of VanEck Pharmaceutical ETF by 2.0% during the 3rd quarter. Axxcess Wealth Management LLC now owns 9,741 shares of the company’s stock valued at $1,066,000 after purchasing an additional 188 shares in the last quarter. IFP Advisors Inc lifted its position in shares of VanEck Pharmaceutical ETF by 115.7% in the second quarter. IFP Advisors Inc now owns 537 shares of the company’s stock worth $59,000 after buying an additional 288 shares during the last quarter. Finally, Fifth Third Bancorp lifted its holdings in VanEck Pharmaceutical ETF by 357.1% in the 3rd quarter. Fifth Third Bancorp now owns 512 shares of the company’s stock worth $56,000 after purchasing an additional 400 shares during the last quarter.

VanEck Pharmaceutical ETF Company Profile

(Get Free Report)

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.

Featured Stories

Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.